斯洛伐克 - 斯洛伐克文 - ŠÚKL (Štátny ústav pre kontrolu liečiv)

baxter czech, spol. s r.o., Česká republika - iné aditíva do intravenóznych roztokov - 76 - infundibilia

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanóm - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - deucravacitinib - svrab - imunosupresíva - treatment of moderate-to-severe plaque psoriasis in adults.

斯洛伐克 - 斯洛伐克文 - Ústav štátnej kontroly veterinárnych biopreparátov a liečiv

genera, chorvátsko - lyof.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

seagen b.v. - tucatinib - breast neoplasms; neoplasm metastasis - antineoplastické činidlá - tukysa is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with her2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑her2 treatment regimens.

欧盟 - 斯洛伐克文 - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastické činidlá - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

斯洛伐克 - 斯洛伐克文 - myHealthbox

bayer ag - olejová disperzia - foramsulfuron 50 g/l; thiencarbazone-methyl 30 g/l